Kymera IPO Presentation Deck

Tumor Regressions from Intermittent Dosing In Preclinical Xenograft Model Both PO and IV • Mice carrying MYD-88 mutated OCI-Ly10 xenografts treated with lead IRAKIMID dosed orally (left) and IV (right) -IRAKIMID induced complete tumor regressions • Responses were seen with different routes of administration and schedules . Durable responses suggest potential for infrequent dosing KYMERA Tumor volume (mm³) Vehicle PO, QD x 7 days Lead IRAKIMID Degrader 10 mg/kg. D1, 4, 8, 11 Lead IRAKIMID Degrader 30 mg/kg. D1, 4,8 2500 2000- 1500- 1000 500 0 7 14 21 28 35 Days Tumor volume (mm³) → IV Vehicle Lead IRAKIMID Degrader 3 mg/kg, D1,4,8,11 Lead IRAKIMID Degrader 6 mg/kg, D1,4,8 2500 2000 1500 1000 500 0 7 14 21 28 35 Days

View entire presentation